Trials in New York.
171 APOE4-relevant Alzheimer’s trials run in New York — 83 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Where
- New York · Rochester · Albany · Syracuse · Amherst · Brooklyn · Staten Island · Buffalo
- Recruiting
- 83 of 171
Non-carriers only, not for APOE4
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
CompletedPhase 3NCT00574132Drug trial for diagnosed APOE4 carriers
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
CompletedPhase 3NCT00575055Carriers enrolled, but higher ARIA risk
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseThis Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
CompletedPhase 2NCT01767311APOE4 response explicitly analyzed
Benfotiamine in Alzheimer's Disease: A Pilot StudyThis trial is testing benfotiamine, a fat-soluble form of vitamin B1, in people with early memory problems or mild Alzheimer's. The idea is that boosting…
CompletedPhase 2NCT02292238Built exclusively for APOE 4/4 carriers
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThis trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
TerminatedPhase 2NCT02565511Built specifically for APOE4 carriers
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThis trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
TerminatedPhase 2NCT03131453Built exclusively for APOE4 homozygotes
Gene Therapy for APOE4 Homozygote of Alzheimer's DiseaseThis Phase 1 trial is testing LX1001, a gene therapy delivered into the spinal fluid, in people who carry two copies of APOE4 and already have…
CompletedPhase 1NCT03634007Excludes APOE4 homozygotes (4/4 carriers)
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's DiseaseThis study tests whether a focused-ultrasound device, guided by MRI, can safely and temporarily open the blood-brain barrier in people with probable…
RecruitingObservationalNCT03671889Open to carriers, but ARIA risk elevated
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseThis Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
ActivePhase 3NCT03887455APOE4 carriers explicitly welcomed
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidThis Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
ActivePhase 3NCT04468659Built exclusively for APOE4/4 carriers
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD SubjectsThis Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
CompletedPhase 3NCT04770220APOE4/4 only, closed to new enrollees
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD SubjectsThis is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
TerminatedPhase 3NCT06304883Drug trial for symptomatic early Alzheimer's
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…
ActivePhase 2NCT06335173APOE4 enrolled, response may differ
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's DiseaseThis Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
CompletedPhase 3NCT00348140Enrolled carriers, prior data unfavorable
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseaseThis trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
CompletedObservationalNCT00348309APOE4 stratified, suggests less benefit
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's DiseaseThis Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
CompletedPhase 3NCT00428090Drug trial, genotype not specified in source
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease PatientsThis trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
TerminatedPhase 3NCT00667810Drug trial, not APOE4-specific, carriers at risk
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease PatientsThis trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…
TerminatedPhase 3NCT00676143Open to carriers, not 4-specific
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's DiseaseThis trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
CompletedPhase 2NCT00710684Rare inherited mutation families, not APOE4
Dominantly Inherited Alzheimer Network (DIAN)This is an observational study, meaning no drug or treatment is given. Researchers follow families with a rare inherited gene mutation that causes Alzheimer's,…
RecruitingNCT00869817Drug extension study, prior participants only
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease PatientsThis trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…
TerminatedPhase 3NCT00998764Cancer trial, not for healthy carriers
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain MetastasesThis trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…
CompletedPhase 2NCT01227954Huntington's study, not about APOE4
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease CohortEnroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…
RecruitingNCT01574053Not Alzheimer's, not APOE4-specific
Natural History Study of SynucleinopathiesThis is an observational study, not a drug test. Researchers follow people with synucleinopathies, such as Parkinson disease, Lewy body dementia, and multiple…
RecruitingNCT01799915Amyloid-focused, drug did not succeed
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossThis Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
CompletedPhase 3NCT02008357Open to carriers, not 4-specific
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's DiseaseThis trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
TerminatedPhase 2NCT02245737Lymphoma study, not Alzheimer's-related
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin LymphomasThis study looks at whether a blood test can spot aggressive B-cell lymphoma coming back after first-round chemotherapy. The test reads tumor DNA left in the…
ActiveNCT02633111Retired NHL players only, not APOE4-specific
Effects of Multiple Concussions in Retired NHL PlayersThis study looks at how multiple concussions affect retired NHL players years later. Researchers measure thinking, balance, body position sense, mood,…
TerminatedNCT02746523Open to carriers, not 4-specific
Exercise in Adults With Mild Memory ProblemsThis trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…
CompletedObservationalNCT02814526Heart trial, genotype not relevant
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionThis Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
CompletedPhase 3NCT02884206Observational only, no treatment involved
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
ActiveNCT02951598Discontinued trial, not APOE4-specific
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaThis Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
TerminatedPhase 3NCT02972658Open to carriers, not 4-specific
Escitalopram for Agitation in Alzheimer's DiseaseThis Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
ActivePhase 3NCT03108846Observational only, genotype not specified
Sleep Aging and Risk for Alzheimer's 2.0This study is tracking whether poor sleep and sleep apnea speed up amyloid buildup in the brain. Participants get two nights of sleep monitoring in a lab plus…
ActiveNCT03278119Imaging study, not APOE4-specific
Tau PET in Imaging and Cognition: Healthy Adults From 55-90This study uses a brain scan tracer called 18F-MK-6240 to look for tau, a protein that builds up in Alzheimer's, in healthy older adults and people with mild…
RecruitingNCT03372317Not relevant: ALS records study, no APOE4
Clinical Procedures to Support Research in ALSThis study uses information already in the medical records of people with ALS and related conditions to learn more about those diseases. It tests no drug or…
RecruitingNCT03489278Open to carriers, not 4-specific
Longitudinal Early-onset Alzheimer's Disease Study ProtocolLEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
ActiveNCT03507257Open to carriers, not 4-specific
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer'sThe LUCINDA Trial is testing whether leuprolide acetate, a hormone-suppressing drug already used for other conditions, can slow cognitive decline when added to…
CompletedPhase 2NCT03649724Not APOE4-related; inherited ALS families only
Amyotrophic Lateral Sclerosis (ALS) Families ProjectThis is an observational study of families affected by inherited ALS, a disease of the motor neurons. Researchers follow people who carry an ALS gene mutation…
RecruitingNCT03865420Genotype irrelevant, community-specific trial
PLAN: Dementia Literacy Education and Navigation for Korean Elders With Probable Dementia and Their CaregiversThis trial is testing a community health worker program called PLAN, designed to help Korean American elders who may have undiagnosed dementia get connected to…
CompletedObservationalNCT03909347Not APOE4-related, movement disorder focus
Trial of Parkinson's And Zoledronic AcidThis trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
CompletedPhase 4NCT03924414Late-stage dementia care, not prevention
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)This trial is testing whether electroconvulsive therapy (ECT) — brief, controlled electrical stimulation of the brain — can safely reduce severe agitation in…
CompletedObservationalNCT03926520Open to carriers, genotype not tracked
Metformin in Alzheimer's Dementia PreventionThis trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
ActivePhase 2NCT04098666Open to carriers, not 4-specific
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…
ActivePhase 2NCT04148391Not relevant to APOE4 carriers
Trial-Ready Cohort-Down Syndrome (TRC-DS)This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
RecruitingNCT04165109Observational study, genotype not specified
Autoimmune Features of Neurodegenerative DisordersThis is an observational study, so nothing is being tested as a treatment. Researchers will take blood samples and give short questionnaires to people with…
RecruitingNCT04239079Open to carriers, not 4-specific
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older AdultsPREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
RecruitingPhase 4NCT04262206Not Alzheimer's-related; no APOE4 relevance
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabThis trial tests a three-drug combination (daratumumab, pomalidomide, and dexamethasone) in people with AL amyloidosis whose disease came back or stopped…
ActivePhase 2NCT04270175FTLD-focused, not APOE4-relevant
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
RecruitingNCT04363684High ARIA risk for carriers
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
ActivePhase 3NCT04437511
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.